Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Puma Biotechnology Inc

PBYI
Current price
2.99 USD 0 USD (0.00%)
Last closed 3.21 USD
ISIN US74587V1070
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 141 254 496 USD
Yield for 12 month -21.32 %
1Y
3Y
5Y
10Y
15Y
PBYI
21.11.2021 - 28.11.2021

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. Address: 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.33 USD

P/E ratio

15.1579

Dividend Yield

Current Year

+235 637 000 USD

Last Year

+228 000 000 USD

Current Quarter

+56 136 000 USD

Last Quarter

+47 083 000 USD

Current Year

+172 955 000 USD

Last Year

+172 900 000 USD

Current Quarter

+27 039 000 USD

Last Quarter

+36 425 000 USD

Key Figures PBYI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 44 678 000 USD
Operating Margin TTM 27.45 %
PE Ratio 15.1579
Return On Assets TTM 6.02 %
PEG Ratio 0.03
Return On Equity TTM 22.1 %
Wall Street Target Price 4.33 USD
Revenue TTM 243 536 992 USD
Book Value 1 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 43.5 %
Dividend Yield
Gross Profit TTM 172 938 000 USD
Earnings per share 0.19 USD
Diluted Eps TTM 0.19 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY 241.7 %
Profit Margin 9.56 %

Dividend Analytics PBYI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History PBYI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation PBYI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 15.1579
Forward PE 3.8926
Enterprise Value Revenue 0.6526
Price Sales TTM 0.58
Enterprise Value EBITDA 4.0789
Price Book MRQ 2.9119

Financials PBYI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators PBYI

For 52 weeks

2.23 USD 7.73 USD
50 Day MA 2.67 USD
Shares Short Prior Month 3 411 953
200 Day MA 3.99 USD
Short Ratio 13.35
Shares Short 3 615 755
Short Percent 8.69 %